This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the first quarter, driven by revived demand.
Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.
Novavax (NVAX) Stock Moves -0.25%: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $236.93, marking a -0.25% move from the previous day.
Novavax Vaccine to Get U.S. Approval? ETFs to Benefit
by Sanghamitra Saha
Novavax (NVAX) is reportedly set to receive the fourth authorization for COVID-19 vaccine in the United States.
Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FAD
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming first-quarter earnings call, investor focus is expected to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Novavax (NVAX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $207.61, marking a +0.15% move from the previous day.
Novavax (NVAX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $202.09, marking a +0.37% move from the previous day.
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $179.74 in the latest trading session, marking a +1.97% move from the prior day.
Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Company News for Apr 7, 2021
by Zacks Equity Research
Companies in The News Are: ILMN, NVAX, MRNA, BP.
Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Novavax (NVAX) Stock Moves -0.25%: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $173.32, marking a -0.25% move from the previous day.
Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.
Follow Dave Portnoy & Reddit Rebellion with These ETFs
by Neena Mishra
These ETFs track social media sentiment & market trends.
Bull of the Day: Meridian Bioscience (VIVO)
by Kevin Cook
Delay in FDA approval for latest COVID test hasn't altered growth or value at 3X sales
Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $225.46, marking a +1.45% move from the previous day.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron Pharma, Sanofi, Novavax and Translate Bio
A Pureplay ETF on Leisure from SonicShares in the Offing
by Sanghamitra Saha
SonicShares recently filed for an Airlines, Hotels, Cruise Lines ETF.
Biotech Stock Roundup: REGN's Cancer Drug Positive, COVID-19 Updates From NVAX & More
by Zacks Equity Research
The biotech sector was in focus last week with vaccine and antibody updates from quite a few companies like Novavax (NVAX) and Vir (VIR), among others.
A Guide to Small-Cap Value ETF Investing
by Sanghamitra Saha
The U.S. small-cap index the Russell 2000 has outperformed its bigger peer equity gauges by wide margin this year.
A Guide to Small-Cap Value ETF Investing
by Sanghamitra Saha
The U.S. small-cap index the Russell 2000 has outperformed its bigger peer equity gauges by wide margin this year.
Top-Performing ETF Areas of Last Week
by Sanghamitra Saha
The passage of the $1.9 trillion COVID-19 relief bill and tame inflation data boosted the markets last week.
6 Top Leveraged ETF Areas of Last Week
by Sanghamitra Saha
The S&P 500, the Dow Jones, the Nasdaq Composite and the small-cap Russell 2000 were all on an uptrend last week.
Novavax's (NVAX) COVID-19 Vaccine Shows Final Efficacy of 96.4%
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves to be 96.4% effective in final analysis in the phase III study in the United Kingdom. Shares up.